The safety and efficacy of doses higher than 0.5 mg/day of dutasteride in male androgenic alopecia
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Authors
- Pedro José Fernández Esparcia (ORCID: https://orcid.org/0009-0004-7335-777X)
- David Saceda‐Corralo (ORCID: https://orcid.org/0000-0001-6315-5462)
- Adrián Imbernón‐Moya (ORCID: https://orcid.org/0000-0002-6520-9070)
- Juan Jimenez‐Cauhe (ORCID: https://orcid.org/0000-0002-6190-0147)
- Diego Buendía‐Castaño (ORCID: https://orcid.org/0000-0003-4551-6353)
- Rocío Gil‐Redondo (ORCID: https://orcid.org/0000-0003-3794-0402)
- Ángela Hermosa‐Gelbard (ORCID: https://orcid.org/0000-0002-0152-9526)
- Sergio Vañó‐Gaván
Institutions
- Instituto Cajal (ES)
- Hospital Universitario La Paz (ES)
- Hospital Universitario Severo Ochoa (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2026-09-29
- DOI
- https://doi.org/10.1111/jdv.70780
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00